Evidence map›Paper›PMID 38888766›Full record

ArticleCancer chemotherapy and pharmacology2024

Alterations in pharmacogenetic genes and their implications for imatinib resistance in Chronic Myeloid Leukemia patients from an admixed population.

Karla Beatriz Cardias Cereja-Pantoja, Tereza Cristina de Brito Azevedo, Lui Wallacy Morikawa Souza Vinagre, Francisco Cezar Aquino de Moraes, Giovanna Gilioli da Costa Nunes, Natasha Monte, Angélica Leite de Alcântara, Amanda Cohen-Paes, Marianne Rodrigues Fernandes, Sidney Emanuel Batista Dos Santos and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Karla Beatriz Cardias Cereja-PantojaNúcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, PA, 66073-005, Brazil.
Tereza Cristina de Brito AzevedoOphir Loyola Hospital, Belém, PA, 66063-240, Brazil.
Lui Wallacy Morikawa Souza VinagreNúcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, PA, 66073-005, Brazil.
Francisco Cezar Aquino de MoraesNúcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, PA, 66073-005, Brazil. francisco.cezar2205@gmail.com.ORCID 0000-0003-0623-8135
Giovanna Gilioli da Costa NunesNúcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, PA, 66073-005, Brazil.
Natasha MonteNúcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, PA, 66073-005, Brazil.
Angélica Leite de AlcântaraNúcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, PA, 66073-005, Brazil.
Amanda Cohen-PaesNúcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, PA, 66073-005, Brazil.
Marianne Rodrigues FernandesNúcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, PA, 66073-005, Brazil.
Sidney Emanuel Batista Dos SantosNúcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, PA, 66073-005, Brazil.
Paulo Pimentel de AssumpçãoNúcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, PA, 66073-005, Brazil.
Ândrea Kely Ribeiro Dos SantosNúcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, PA, 66073-005, Brazil.
Rommel Mario Rodríguez BurbanoOphir Loyola Hospital, Belém, PA, 66063-240, Brazil.
Raquel Cruz GuerreroCentro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas - CiMUS, Universidad de Santiago de Compostela, Santiago de Compostela, 15782, Spain.
Ángel CarracedoCentro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas - CiMUS, Universidad de Santiago de Compostela, Santiago de Compostela, 15782, Spain.
Ney Pereira Carneiro Dos SantosNúcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, PA, 66073-005, Brazil.

Funding

Pró-Reitoria de Pesquisa e Pós-Graduação, Universidade Federal do Pará Pró-Reitoria de Pesquisa e Pós-Graduação, Universidade Federal do Pará
6 · The paper itself

Abstract

Imatinib is the tyrosine kinase inhibitor used as the gold standard for the treatment of Chronic Myeloid Leukemia. However, about 30% of patients do not respond well to this therapy. Variants in drug administration, distribution, metabolism and excretion (ADME) genes play an important role in drug resistance especially in admixed populations. We investigated 129 patients diagnosed with Chronic Myeloid Leukemia treated with imatinib as first choice therapy. The participants of the study are highly admixed, populations that exhibit genetic diversity and complexity due to the contributions of multiple ancestral groups. Thus, the aim of this work was to investigate the association of 30 SNVs in genes related to response to treatment with Imatinibe in CML. Our results indicated that for the rs2290573 of the ULK3 gene, patients with the recessive AA genotype are three times more likely to develop resistance over time (secondary resistance) (p = 0.019, OR = 3.19, IC 95%= 1.21-8.36). Finally, we performed interaction analysis between the investigated variants and found several associations between SNVs and secondary resistance. We concluded that the variant rs2290573 of the ULK3 gene may be relevant for predicting treatment response of CML with imatinib, as well as possible treatment resistance. The use of predictive biomarkers is an important tool for therapeutic choice of patients, improving their quality of life and treatment efficacy.

Indexed as

Antineoplastic AgentsDrug Resistance, NeoplasmImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositivePolymorphism, Single NucleotideProtein Kinase InhibitorsAdultAgedFemaleGenotypeHumansMaleMiddle AgedPharmacogeneticsYoung AdultAntineoplastic AgentsImatinib MesylateProtein Kinase InhibitorsChronic myeloid leukemiaImatinibTherapyVariants

Identifiers

PMID38888766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.